Despite the relative novelty of the human microbiome as an area of study, a substantial body of evidence has accumulated addressing its potential involvement in the pathogenesis of rheumatic disease. This review article explores the available data in animal and human studies, focusing on the role of the intestinal microbiome in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and the spondyloarthritidies (SpA)…
New SLE Drug May Allow Patients to Reduce Steroid Use
In a recent study, the use of anifrolumab in SLE patients was shown to be safe and effective, enabling some patients to decrease their oral steroids. Also, secukinumab has been approved in Europe to treat ankylosing spondylitis and psoriatic arthritis…
Bone Loss Common in Suspected Spondyloarthritis
NEW YORK (Reuters Health)—More than 40% of patients with early inflammatory back pain suggestive of axial spondyloarthritis (SpA) show bone loss over the course of two years, according to French researchers. SpA is known to be associated with bone loss at the spine and the hip and an increased risk of vertebral fractures. To investigate…
Subcutaneous Golimumab in Active Non-Radiographic Axial Spondyloarthritis
Patients with non-radiographic axSpA experience reduced mobility and quality of life. In this study, researchers investigated the effect of treatment for nr-axSpA every four weeks with SQ golimumab (GLM). Seventy-one percent of patients in the GLM group achieved ASAS 20 response at Week 16, compared with 40.0% in the control group…
ACR’s New AS & Nonradiographic Axial SpA Treatment Recommendations
ATLANTA—The American College of Rheumatology (ACR) has released new recommendations for the treatment of ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (SpA). The guideline was developed with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network. It summarizes recommendations for both pharmacologic and non-pharmacologic treatments, including rehabilitation, management of patients with…
EULAR 2015: Emerging Concepts, Treatments for Axial Spondyloarthritis
ROME, Italy—When it comes to thinking about disease modification—a main goal in the treatment of axial spondyloarthritis (axial SpA) and other inflammatory diseases—it’s time to reconsider the concept, an expert said at EULAR 2015, the annual congress of the European League Against Rheumatism (EULAR). The traditional way of assessing disease modification, inhibiting radiographic progression, is…
Odds Ratio Explained for MRI Imaging in Ankylosing Spondylitis
In the lead article, “Imaging in Ankylosing Spondylitis” (The Rheumatologist, April 2015), Dr. Pedersen states, “vertebral edges with MRI inflammation were three times as likely to develop new syndesmophytes than vertebral edges without inflammation (odds ratio [OR] 3.3; 95% CI: 1.5–7.4).” This statement is incorrect. An odds ratio of 3 does not imply that an…
Inspiratory Muscle Training Boosts Lung Strength in Ankylosing Spondylitis
NEW YORK (Reuters Health)—Inspiratory muscle training can help improve aerobic capacity and pulmonary function in patients with ankylosing spondylitis (AS), according to new findings presented at the European League Against Rheumatism Annual Congress. “Inspiratory muscle training as a stand-alone therapy improves inspiratory muscle function (strength and endurance), decreases symptoms of dyspnea and improves exercise capacity,”…
Anti-TNF Agents May Improve Clinical Symptoms of Ankylosing Spondylitis
Ankylosing spondylitis primarily affects the joints and ligaments of the spine, but may also have an impact on other joints. Patients experience pain and stiffness that limit mobility in the back and other affected joints. Symptoms can come and go, last for long periods of time and be severe. Anti-tumor necrosis factor (anti-TNF) drugs are…
Imaging in Ankylosing Spondylitis
MRI inflammation, fat and new bone formation in the sacroiliac joints, spine in patients with AS
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 19
- Next Page »